<DOC>
	<DOCNO>NCT01679002</DOCNO>
	<brief_summary>To investigate steady-state pharmacokinetics once-daily twice-daily regimen BIA 2-093 twice-daily regimen Oxcarbazepine ( Trileptal® ) healthy subject assess tolerability regimens healthy subject .</brief_summary>
	<brief_title>Steady-state Pharmacokinetics BIA 2-093 Oxcarbazepine Healthy Volunteers</brief_title>
	<detailed_description>Single centre , open-label , randomised , three-way crossover study 12 healthy volunteer . The study consist three 8-day treatment period separate washout period 10-15 day . On treatment period volunteer receive either daily oral dose BIA 2-093 900 mg once-daily ( od ) , BIA 2-093 450 mg twice-daily ( bid ) , Oxcarbazepine ( Trileptal® ) 450 mg bid .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<mesh_term>Oxcarbazepine</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>Subjects eligible entry study fulfil follow inclusion criterion : Male female subject age 18 45 year , inclusive . Subjects body mass index ( BMI ) 19 28 kg/m2 , inclusive . Subjects healthy determine prestudy medical history , physical examination , neurological examination , 12lead ECG . Subjects clinical laboratory test clinically acceptable . Subjects negative HBsAg , antiHCV Ab HIV1 HIV2 Ab test screen . Subjects negative alcohol drug abuse screen first admission . Subjects nonsmoker smoke less 10 cigarette equivalent per day . Subjects able willing give write informed consent . If case female subject , subject childbearing potential reason surgery , childbearing potential , use one follow method contraception : doublebarrier , intrauterine device abstinence . If case female subject , subject negative pregnancy test screen first admission . Subjects conform inclusion criterion . Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue diseases disorder . Subjects clinically relevant surgical history . Subjects clinically relevant family history . Subjects history relevant atopy . Subjects history hypersensitivity carbamazepine oxcarbazepine relevant drug hypersensitivity . Subjects history alcoholism drug abuse . Subjects consume 14 unit alcohol week . Subjects significant infection know inflammatory process screen and/or first admission . Subjects acute gastrointestinal symptom time screen and/or first admission ( e.g. , nausea , vomit , diarrhoea , heartburn ) . Subjects use prescription overthecounter medication within two week first admission . Subjects use investigational drug and/or participate clinical trial within four month first admission . Subjects previously receive BIA 2093 . Subjects donate and/or receive blood blood product within previous 4 month prior screen . Subjects vegetarian , vegan and/or medical dietary restriction . Subjects could communicate reliably investigator . Subjects unlikely cooperate requirement study . Subjects unwilling unable give write informed consent . In case female subject , subject pregnant breastfeeding . In case female subject , subject childbearing potential use approve effective contraceptive method use oral contraceptive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Oxcarbazepine</keyword>
	<keyword>Eslicarbazepine Acetate</keyword>
	<keyword>BIA 2-093</keyword>
</DOC>